VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ERIC 2022 | How patients are involved in treatment decisions following a genomic test

Michel van Gelder, MD, PhD, Maastricht University, Maastricht, Netherlands, shares some insights into how patients with chronic lymphocytic leukemia (CLL) are involved in treatment decision-making following a genomic test, highlighting the availability of various therapeutic options in The Netherlands, including chemoimmunotherapy (CIT) and novel agents. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter